Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13729434 | 0.98 | KDM4E (0.41) | KDM4EALDH1A1HCAR2POLBASPH | |
| SCHEMBL29465147 | 0.82 | DGAT1 (0.35) | KDM4EALDH1A1HCAR2POLBASPH | |
| SCHEMBL1661089 | 0.82 | DGAT1 (0.35) | KDM4EALDH1A1HCAR2POLBASPH | |
| SCHEMBL10081962 | 0.82 | DGAT1 (0.35) | KDM4EALDH1A1HCAR2POLBASPH | |
| SCHEMBL1629161 | 0.82 | DGAT1 (0.47) | KDM4EALDH1A1HCAR2POLBDGAT1 | |
| SCHEMBL17224823 | 0.79 | GSK3B (0.37) | KDM4EALDH1A1HCAR2POLBDGAT1 | |
| SCHEMBL107357 | 0.79 | HCAR2 (0.45) | KDM4EHCAR2ASPHKDM8BACE1 | |
| SCHEMBL4976345 | 0.79 | ALDH1A1 (0.45) | KDM4EALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL15543442 | 0.78 | NPSR1 (0.41) | HTT | |
| SCHEMBL16978524 | 0.78 | CFTR (0.40) | KDM4ESMN1; SMN2BACE1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | MERCK SHARP & DOHME CORP. | 2008-12-25 | — | — | US | disclosed |
| US-20070189865-A1 | Amino cyclopropane carboxamide derivatives as bradykinin antagonists | MERCK & CO., INC. | 2007-08-16 | — | — | US | disclosed |
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1723143-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1706372-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | Merck & Co., Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| WO-2005085198-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005063690-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | MERCK & CO., INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1545538-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019868-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | LPAR1, LPAR2, LPAR3 | KDM4E 3237/4885ALDH1A1 1600/4885HCAR2 34/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | KDM4E 3825/4885ALDH1A1 2200/4885HCAR2 4498/4885 |
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | BDKRB1, BDKRB2, HCAR2 | KDM4E 3334/4885ALDH1A1 2631/4885HCAR2 3/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | KDM4E 4647/4885ALDH1A1 1707/4885HCAR2 3050/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | KDM4E 627/4885ALDH1A1 1185/4885HCAR2 4035/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | KDM4E 3997/4885ALDH1A1 1858/4885HCAR2 4289/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885ALDH1A1 868/4885HCAR2 87/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | KDM4E 2102/4885ALDH1A1 256/4885HCAR2 2070/4885 |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | KDM4E 4171/4885ALDH1A1 3311/4885HCAR2 6/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 4653/4885ALDH1A1 966/4885HCAR2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.